Published in PLoS One on January 31, 2007
Dysfunctional transforming growth factor-β signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer (2011) 1.63
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A (2010) 1.41
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
Molecular mechanisms of Barrett's esophagus. Dig Dis Sci (2011) 0.89
Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis. Clin Transl Gastroenterol (2012) 0.82
Cooperative assembly of Co-Smad4 MH1 with R-Smad1/3 MH1 on DNA: a molecular dynamics simulation study. PLoS One (2013) 0.80
Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget (2015) 0.77
New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB J (2016) 0.75
TGF-β1 regulates the expression and transcriptional activity of TAZ via a Smad3-independent, myocardin-related transcription factor-mediated mechanism. J Biol Chem (2017) 0.75
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol (2001) 4.87
Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature (1998) 4.13
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci U S A (1986) 2.93
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem (1991) 2.52
Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem (1995) 1.89
Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem (1991) 1.61
Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol (1998) 1.49
Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene (1991) 1.37
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem (2001) 1.33
C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res (2003) 1.32
Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer (1998) 1.27
Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol (2002) 1.24
TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci (2001) 1.21
Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem (1992) 1.16
Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene (2004) 1.14
PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. J Cell Physiol (2000) 1.10
Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut (2005) 1.03
Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells. Cancer Res (2005) 1.02
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer (1994) 1.01
Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer (2000) 0.97
Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem (1995) 0.94
Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur J Biochem (1996) 0.92
RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery (2004) 0.90
Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann Surg (2001) 0.89
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans (2002) 0.86
MEKK1 is required for inducible urokinase-type plasminogen activator expression. J Biol Chem (2002) 0.85
Plasminogen activators in oesophageal carcinoma. Br J Surg (1996) 0.81
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. Clin Exp Metastasis (1999) 0.81
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med (2012) 1.83
Retinoic acid-induced glandular differentiation of the oesophagus. Gut (2006) 1.75
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol (2005) 1.65
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology (2010) 1.43
In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res (2006) 1.41
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A (2010) 1.41
Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology (2012) 1.37
Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res (2003) 1.26
Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology (2007) 1.23
A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol (2013) 1.21
Screening for oesophageal cancer. Nat Rev Clin Oncol (2012) 1.13
Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology (2012) 1.13
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res (2004) 1.12
Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol (2013) 1.06
Genetic predisposition to gastro-oesophageal cancer. Curr Opin Genet Dev (2010) 1.06
A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut (2012) 1.05
Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med (2011) 1.02
Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res (2007) 1.00
Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc Natl Acad Sci U S A (2012) 0.99
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98
Massive urinary ascites after removal of a supra-pubic catheter: case report and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.97
Cellular origin of Barrett's metaplasia and oesophageal stem cells. Biochem Soc Trans (2010) 0.95
Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.95
Treatment for Barrett's oesophagus. Cochrane Database Syst Rev (2010) 0.93
Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol (2007) 0.93
Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology (2012) 0.92
DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res (2012) 0.90
Biomarkers for dysplastic Barrett's: ready for prime time? World J Surg (2015) 0.89
Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis (2005) 0.88
Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia (2005) 0.88
Role of the micro-environment in Barrett's carcinogenesis. Biochem Soc Trans (2010) 0.88
The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg (2014) 0.87
Familial gastric cancer - aetiology and pathogenesis. Best Pract Res Clin Gastroenterol (2006) 0.86
Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J Pathol (2013) 0.86
Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet (2009) 0.84
Clinical puzzle: Barrett's oesophagus. Dis Model Mech (2008) 0.82
Research advances in esophageal diseases: bench to bedside. F1000Prime Rep (2013) 0.82
Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol (2013) 0.81
Cellular mechanisms of Barrett's esophagus development. Surg Oncol Clin N Am (2009) 0.81
Let's not jump to conclusions regarding low-grade dysplasia in Barrett's esophagus. Gastroenterology (2012) 0.79
Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. Carcinogenesis (2010) 0.79
Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med (2008) 0.78
Significance of acid exposure in Barrett's esophagus. Am J Gastroenterol (2003) 0.78
Screening and risk stratification for Barrett's esophagus: how to limit the clinical impact of the increasing incidence of esophageal adenocarcinoma. Gastroenterol Clin North Am (2013) 0.78
Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. World J Surg (2014) 0.77
Diagnosis and treatment of Barrett's oesophagus. Br Med Bull (2013) 0.77
Barrett's oesophagus and adenocarcinoma. World J Surg Oncol (2004) 0.76
Non-endoscopic immunocytological screening test for Barrett's oesophagus. Gut (2007) 0.76
Barrett's esophagus. Gastroenterol Clin North Am (2008) 0.76
Fluorescence imaging for the detection of early neoplasia in Barrett's esophagus: old looks or new vision? Eur J Gastroenterol Hepatol (2014) 0.75
The definition and management of Barrett's oesophagus: a case report, review of the literature and a suggestion for the future. BMJ Case Rep (2009) 0.75
Oracular guidance on clinical management of early neoplastic Barrett's esophagus. Gastroenterology (2012) 0.75
Gastrin-induced hyperproliferation in Barrett's esophagus. Gastroenterology (2003) 0.75
Where is the truth when it comes to cancer risk in Barrett's esophagus? Gastroenterology (2012) 0.75
Corrigendum: A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. Genome Res (2017) 0.75
Do transcription factors hold the key to understanding the development of Barrett's esophagus? Dig Dis Sci (2012) 0.75
Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. Expert Opin Med Diagn (2007) 0.75
Corrigendum: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2017) 0.75
Barrett's oesophagus: diagnosis, surveillance and treatment. Br J Hosp Med (Lond) (2013) 0.75